Last update May 11, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Terazosin Hydrochloride is also known as
Terazosin Hydrochloride in other languages or writings:
Terazosin Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Terazosin Hydrochloride in its composition:
|Tmax||1 - 2||hours|
|T½||9 - 12||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy.
Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (moderately elevated molecular weight and high plasma protein binding and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts and its subsequent absorption by the infant.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Anderson 2018, Malachias 2016, Schaefer 2007 p685), especially during the neonatal period and in case of prematurity